{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060399","form_type":"8-K","ticker":"PSTV","cik":"0001095981","company_name":"PLUS THERAPEUTICS, INC.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.263780+00:00","generated_at":"2026-06-01T22:35:09.804314+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Plus Therapeutics Q1 2024 net loss $3.3M; cash $3M; secures up to $19.25M financing","bullets":["Net loss of $3.3M ($0.75 per share) vs $4.8M ($2.07) in Q1 2023; grant revenue rose to $1.7M from $0.5M.","Cash balance $3.0M at March 31, 2024, down from $8.6M at December 31, 2023.","Closed private placement for initial $7.25M with potential total of $19.25M from healthcare funds and insiders.","Received $3M Department of Defense grant recommendation for Phase 1 rhenium obisbemeda trial in pediatric brain cancer.","Acquired exclusive rights to CNSide leptomeningeal metastases diagnostic; reported positive top-line FORESEE trial data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060399","json":"https://secwatch.observer/filing/0000950170-24-060399.json","markdown":"https://secwatch.observer/filing/0000950170-24-060399.md","text":"https://secwatch.observer/filing/0000950170-24-060399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1095981/000095017024060399/0000950170-24-060399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1095981/000095017024060399/pstv-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:35:09.804314+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4109027e3ed3a82948a616fa239d5818fb30b0bf","claim":"PLUS THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: revenue $1.7 million in grant revenue, net income $3.3 million, EPS $(0.75) per share.","evidence_excerpt":"FIRST QUARTER 2024 FINANCIAL RESULTS • The Company’s cash balance was $3 million at March 31, 2024 compared to $8.6 million at December 31, 2023. • The Company recognized $1.7 million in grant revenue in the first quarter of 2024 compared to $0.5 million in the first quarter of 2023, which represents CPRIT’s share of the costs incurred for the Company’s rhenium ( 186 Re) obisbemeda development for the treatment of patients with LM • Total operating loss for the first quarter of 2024 was $3.3 million compared to $4.8 million in the same period of 2023. The decrease was primarily due to increased grant revenue • Net loss for first quarter of 2024 was $3.3 million, or $(0.75) per share, compared to a net loss of $4.8 million, or $(2.07) per share, for the same period the prior year","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1095981/000095017024060399/0000950170-24-060399-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$1.7 million in grant revenue"},{"label":"Net income","value":"$3.3 million"},{"label":"EPS","value":"$(0.75) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}